Brick & Kyle Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

Brick & Kyle Associates’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-130	Closed	-$50K	–	307
2017 Q1	$50K	Hold	130	–	–	0.04%	174
2016 Q4	$48K	Hold	130	–	–	0.04%	180
2016 Q3	$52K	Hold	130	–	–	0.04%	178
2016 Q2	$45K	Hold	130	–	–	0.04%	189
2016 Q1	$47K	Hold	130	–	–	0.04%	179
2015 Q4	$71K	Hold	130	–	–	0.06%	144
2015 Q3	$60K	Hold	130	–	–	0.06%	150
2015 Q2	$66K	Hold	130	–	–	0.06%	151
2015 Q1	$59K	Hold	130	–	–	0.05%	165
2014 Q4	$53K	Buy	+130	New	+$51.1K	0.05%	174

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return

Brick & Kyle Associates's REGN Position: Q2 2017 in Review

Brick & Kyle Associates sold out of Regeneron Pharmaceuticals (REGN) in Q2 2017, closing a stake of 130 shares — an estimated $50K sold.

Brick & Kyle Associates first reported a position in REGN in Q4 2014 and held it in 10 quarters. The position peaked at $71K in Q4 2015. 604 funds tracked by Wall St. Rank hold REGN as of Q2 2017.

Brick & Kyle Associates reported no remaining Regeneron Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
Brick & Kyle Associates sold 130 Regeneron Pharmaceuticals shares in Q2 2017, an estimated $50K.
Brick & Kyle Associates first reported a position in Regeneron Pharmaceuticals in Q4 2014 and held it in 10 quarters.
Brick & Kyle Associates's Regeneron Pharmaceuticals position peaked at $71K in Q4 2015.
604 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2017.

Based on Brick & Kyle Associates's 13F filing for Q2 2017, filed 14 Aug 2017.